Tirosint costs significantly more than generic levothyroxine tablets because it uses a specialized soft gel capsule formulation, faces almost no generic competition, and is manufactured by a single company. While a month of generic levothyroxine tablets might cost $4 to $20, Tirosint can run several hundred dollars without insurance. Several factors work together to keep that price high.
A Simpler Formula That Costs More to Make
The core difference between Tirosint and standard levothyroxine tablets comes down to what’s inside. Generic levothyroxine tablets contain a long list of inactive ingredients: fillers, binders, dyes, and coating agents that help form the pill and give it a long shelf life. Tirosint strips almost all of that away. The soft gel capsule version contains levothyroxine dissolved in glycerin, sealed inside a gelatin shell. The liquid solution version (Tirosint-SOL) contains only glycerin and water alongside the active ingredient.
That simplicity is a selling point for patients who react to the fillers in standard tablets, but it requires a fundamentally different manufacturing process. Instead of pressing powder into a tablet, the manufacturer dissolves the hormone in glycerin and injects it into individual gelatin capsules. This process is more complex and more expensive to scale than standard tablet production, and it’s handled by a single manufacturer, IBSA Institut Biochimique, a Swiss pharmaceutical company. When one company controls the entire production pipeline for a specialized dosage form, there’s little market pressure to lower costs.
No Real Generic Competition
Generic competition is the single biggest factor that drives drug prices down, and Tirosint has had almost none. While the FDA has technically approved authorized generic versions of Tirosint capsules through a company called YARAL Pharma (covering all strengths from 13 to 200 micrograms), these products do not appear to be commercially available. They exist on paper but haven’t launched in pharmacies. Until a competing product actually reaches the market, Tirosint’s manufacturer can effectively set prices without competitive pressure.
This situation is different from standard levothyroxine tablets, where dozens of generic manufacturers compete with each other and with brand names like Synthroid. That competition keeps tablet prices low. Tirosint occupies a niche where its unique dosage form insulates it from that price erosion.
Better Absorption in Specific Situations
Part of what sustains Tirosint’s pricing is that it genuinely performs differently from tablets for certain patients, giving doctors clinical reasons to prescribe it despite the cost. The gel capsule dissolves rapidly in the stomach’s acidic environment, and the pre-dissolved hormone doesn’t depend on the same digestive steps that tablets require.
In a study of 31 patients with stomach-related absorption problems, switching from tablet levothyroxine to the soft gel capsule allowed roughly two-thirds of them to reduce their dose while maintaining the same thyroid hormone levels. The capsule also overcomes interference from coffee and proton pump inhibitors (common acid reflux medications), both of which can reduce how much levothyroxine your body absorbs from a standard tablet. Even patients who took Tirosint just 30 minutes before breakfast, rather than the typical 60-minute wait, showed improved thyroid hormone levels compared to tablets taken on the same schedule.
Overall, Tirosint’s bioavailability is approximately 103% compared to standard tablets, a modest but meaningful edge. For most patients with straightforward hypothyroidism, that difference isn’t clinically significant. But for people with celiac disease, gastric bypass history, chronic gastritis, or those taking medications that interfere with absorption, the gel capsule can be the difference between stable and unstable thyroid levels. That clinical utility supports the premium price, because the patients who need it often have no equivalent alternative.
Insurance Coverage Is Inconsistent
Many insurance plans treat Tirosint as a non-preferred brand, placing it on a high copay tier or requiring prior authorization. Some plans won’t cover it at all unless a doctor documents that generic tablets have failed. This means patients often face the full retail price or a substantial copay, making the cost feel even steeper compared to generics that sit on the lowest formulary tier.
The manufacturer offers a savings card that brings the cost down to as little as $25 for a 30-day supply or $60 for a 90-day supply for patients with commercial insurance. Uninsured patients can also access similar pricing through the same card. However, the savings card excludes anyone covered by Medicare, Medicaid, TRICARE, or other government programs, which cuts out a large portion of patients who use thyroid medication long-term. The manufacturer also runs a program called Tirosint Direct through participating pharmacies, though it doesn’t publish a fixed price publicly.
Why the Price Stays High
Tirosint’s cost reflects a combination of factors that reinforce each other. A specialized manufacturing process limits who can produce it. The absence of commercially available generics removes competitive pricing pressure. A small but clinically important patient population provides steady demand from people who can’t tolerate or absorb standard tablets. And inconsistent insurance coverage means fewer large payers are negotiating the price down in bulk.
If authorized generics eventually reach the market, prices could drop substantially, as they did when generic versions of Synthroid tablets first appeared. Until that happens, Tirosint remains one of the more expensive options for a medication that millions of people take daily. For patients who absorb tablets normally and don’t react to their inactive ingredients, there’s rarely a clinical reason to pay the premium. For those with documented absorption issues, the cost may be justified, and the manufacturer’s savings programs can reduce the out-of-pocket burden significantly.